Filing Details
- Accession Number:
- 0001179110-12-002247
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-02-09 19:25:54
- Reporting Period:
- 2012-02-07
- Filing Date:
- 2012-02-09
- Accepted Time:
- 2012-02-09 19:25:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1327145 | L Robin Washington | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Svp, Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-02-07 | 23,100 | $38.17 | 35,680 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2012-02-07 | 9,935 | $54.92 | 25,745 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-02-07 | 15,065 | $55.28 | 10,680 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Options (right to buy) | Acquisiton | 2012-02-07 | 23,100 | $0.00 | 23,100 | $38.17 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 69,300 | 2021-01-20 | No | 4 | M | Direct |
Footnotes
- The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- Pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011.
- Sale prices reported for the transactions reported here range from $54.67 to $55.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $55.02 to $55.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Billionaire Hedge Funds
